Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?

Krystal Biotech, Inc. (KRYS) shares soared 4.2% in the last trading session to close at $143.67. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.3% gain over the past four weeks.The stock price gain was observed after Krystal Biotech initiated dosing patients in its phase III IOLITE study of KB803 eye drops for DEB-related corneal damage. As a next-generation version of its approved gene therapy, Vyjuvek, KB803 targets a rare and underserved patient population with no corrective treatments. The decentralized, at-home study design and prior compassionate use data showing strong efficacy further supported investor optimism.This company is expected to post quarterly earnings of $1.31 per share in its upcoming report, which represents a year-over-year change of +52.3%. Revenues are expected to be $102.5 million, up 45.9% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Krystal Biotech, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KRYS going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Krystal Biotech is part of the Zacks Medical - Biomedical and Genetics industry. Coherus Oncology (CHRS), another stock in the same industry, closed the last trading session 5.6% higher at $0.77. CHRS has returned -3.9% in the past month.Coherus Oncology's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.25. Compared to the company's year-ago EPS, this represents a change of -78.6%. Coherus Oncology currently boasts a Zacks Rank of #3 (Hold).Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Krystal Biotech, Inc. (KRYS): Free Stock Analysis Report Coherus Oncology, Inc. (CHRS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks